Why the study?
Ischemia/reperfusion injury is associated with PPCI, prompting comparison of tirofiban and recombinant human pro-urokinase for improving coronary slow flow.
Does recombinant human pro-urokinase improve myocardial blood flow perfusion compared to tirofiban in STEMI patients receiving primary percutaneous coronary intervention?
Does recombinant human pro-urokinase improve myocardial blood flow perfusion compared to tirofiban in STEMI patients receiving primary percutaneous coronary intervention?
Recombinant human pro-urokinase may offer superior immediate myocardial blood flow perfusion compared to tirofiban in STEMI patients undergoing primary PCI, with a similar 30-day safety profile.
Answers are grounded in this paper and cite their sources.
Associated with better perfusion in STEMI PCI; hypothesis-generating, requires RCTs before practice change.
Ischemia/reperfusion (I/R) injury is associated with primary percutaneous coronary intervention (PPCI). The current study was performed to compare the effect of tirofiban and recombinant human pro-urokinase (rh-proUK) on the improvement of coronary slow blood after PPCI.Sixty-five ST elevation myocardial infarction (STEMI) patients treated with rh-proUK and an equal number treated with tirofiban after PPCI were employed in the current study. The clinicopathological information regarding the biochemical parameters, thrombolysis in myocardial infarction (TIMI) grade, hemodynamics parameters, thrombus core (TS), sum-STR, left ventricular ejection fraction (LVEF), blood routine parameters, high-sensitivity C-reactive protein (CRP) level, uric acid, hepatorenal function, electrocardiogram (ECG), and echocardiography before and after the interventions were collected. The differences in those parameters between the 2 groups then compared with assess the treatment effect and side effects associated with the both therapies.The results showed that the TIMI level post-intervention (P = .03), the proportion of TIMI myocardial perfusion grade level III (P = .04), the changes in thrombus score (P < .001) in rh-proUK group were significantly higher than those in tirofiban group while the corrected TIMI Frame Count (CTFC) (P = .02), the incidence of slow flow (P = .02), the thrombus score post-intervention (P < .001), the stent length (P = .02), and the number of receiving administration of sodium nitroprusside (P = .01) were significantly lower than those in tirofiban group. Moreover, the levels of CK (P < .001), CK-MB (P = .01), and NT-proBNP 24-hour post-intervention (P < .02) were significantly lower in rh-proUK group than those in tirofiban group and the sum-STR right after the intervention (P < .03) of rh-proUK group was significantly higher than that of tirofiban group. No significant difference was detected between the 2 therapies regarding major adverse cardiac events (MACE).The findings outlined in the current study showed that the improvement effect of rh-proUK on blood flow condition was stronger right after the intervention and the therapy had a similar safety when compared with tirofiban during a 30-day follow-up.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: